Life Technologies Corporation

  • A Top 2 Positions of a Successful Opportunity Fund

    By Anh HOANG - August 8, 2013 | Tickers: IT, ILMN, LIFE

    Mike Lippert, the portfolio manager of Baron Opportunity Retail Fund, has managed to generate outstanding returns in the past ten years. This fund gets a four star rating from Morningstar, delivering a sweet 10-year-annualized return of 12.40%, beating the S&P 500’s return of only 8.05% during the same period. Year-to-date, it gained by nearly 21%, a bit higher than S&P 500’s gain of 19 more »

  • Is This Diversified Tech Company a Buy?

    By Rupert Nicholson - July 16, 2013 | Tickers: A, LIFE, TMO

    After divesting from Hewett-Packard in 1999, Agilent Technologies (NYSE: A) has rapidly expanded its reach and now has clients across the communications, life sciences, and chemical analysis sectors. The company manufacturers a wide variety of products including DNA microarrays, nuclear magnetic resonance, and vector network analysers. The products are often unique to individual customers, generating a strong bond between the company and its customers as only Agilent's engineers are more »

  • What Can a Top Hedge Fund's Top 2 Holdings Do For You?

    By Madhukar Dubey - July 2, 2013 | Tickers: LIFE, S, TMO

    John Paulson, the billionaire hedge fund manager, is known for maintaining an impressive strength during the sub-prime crisis of 2008. His firm, Paulson & Co, has a market value of $17.72 billion as of March 2013. However, after the sub-prime crisis, the performance of the fund is not very impressive. Its Advantage Fund has generated an average annual return of just 4.1% in the last 5 years. Here is more »

  • Is Life Technologies Overvalued?

    By Saurabh Mishra - June 19, 2013 | Tickers: ABAX, A, LIFE, VIVO, OMCL

    On April 15, Thermo fisher announced its acquisition of Life technologies (NASDAQ: LIFE) for $13.6 billion plus approximately $2.2 billion in net debt. This report analyzes the growth of Life technologies and concludes whether LIFE is over- or undervalued.

    About Life Technologies

    Life technologies produces systems and reagents that enable and simplify biological research within academic, clinical, and commercial research applications.

    First Quarter results and outlook

    Revenue for more »

  • 5 Stocks Billionaire John Paulson Is Betting On

    By Meena Krishnamsetty - May 31, 2013 | Tickers: AU, LIFE, PXP, RLGY, S

    Billionaire John Paulson’s Paulson & Co. has struggled following its spectacular success in shorting the U.S. housing market (and, for a while, being long gold), but Paulson remains one of the most widely followed hedge fund managers. His fund recently filed its 13F with the SEC, disclosing many of its long equity positions as of the end of March; see the filing on the SEC's website. We track more »

  • The Next Generation for Qiagen's Next-Gen Sequencing?

    By Seth Robey - May 31, 2013 | Tickers: ILMN, LIFE, QGEN, TMO | Editor's Choice

    Patient-specific pharmacology used to be a futuristic dream for researches and physicians, but the Human Genome Project has placed the framework for this revolution in patient care at our fingertips. 

    In research labs across the country, genomic studies are uncovering the small genetic changes that underlie countless diseases.  In the clinic, rapid genetic sequencing is contributing to unparalleled diagnostic capabilities.  But without the software to analyze sequencing results, researchers are more »

  • This Biotech Giant Is Continuing Its Growth via M&A

    By Peter Pham - May 13, 2013 | Tickers: ILMN, LIFE, TMO

    A group representing some of the biggest private equity firms in the world, the Blackstone Group, Carlyle Group, KKR, and Singapore’s Temasek Holdings are eyeing California based bio-tech firm Life Technologies (NASDAQ: LIFE). They forwarded a bid of $62 per share, which values the firm at $11 billion. But, the analytical and laboratory equipment behemoth, Thermo Fisher Scientific (NYSE: TMO) came forward with a much higher bid of $75 more »

  • Top Three Performing NASDAQ 100 Stocks for 2013

    By Naomi Warmate-Igwe - May 1, 2013 | Tickers: CELG, LIFE, VRTX

    It should come as no surprise that year to date, the top three performing NASDAQ 100 stocks come from companies in the health care sector. Through April 26th, those companies were Vertex Pharmaceuticals (NASDAQ: VRTX) Celgene Corporation (NASDAQ: CELG) and Life Technologies (NASDAQ: LIFE). As many analysts have predicted, the health care sector is performing exceptionally in 2013, asU.S. firms scramble for their piece of the pie in more »

  • This Deal Brings Benefits Along With a Huge Debt

    By Shas Dey - April 29, 2013 | Tickers: ILMN, LIFE, RHHBY, TMO

    The rumors have finally been put to rest. After three months of a bidding war, Thermo Fisher Scientific (NYSE: TMO) ultimately beat other contenders to acquire Life Technologies (NASDAQ: LIFE) for $76 per share, or approximately $13.6 billion (plus net debt at close).

    This transaction, expected to be completed in 2014, is expected to propel the growth of Thermo Fisher in the area of genetic analysis and molecular diagnostics more »

  • Where's the Profit in this Medical Technology Merger?

    By Mike Thiessen - April 28, 2013 | Tickers: A, LIFE, TMO

    After a long takeover battle, Thermo Fisher Scientific (NYSE: TMO) has agreed on a takeover deal with merger partner, Life Technologies (NASDAQ: LIFE). The cash-and-debt deal would cost roughly $13.6 billion and result in Thermo's assumption of over $2 billion in Life's debt. 

    This deal is notable for several reasons. Among other things, Thermo beat out a consortium of private equity firms with an apparently superior bid more »

  • Forget About Life, Check out This Stock

    By Marshall Hargrave - April 22, 2013 | Tickers: A, LIFE, PKI, TMO

    The big news in the medical service and device sector is the speculated buyout of Life Technologies (NASDAQ: LIFE). However, I believe investors could snatch up Agilent Technologies (NYSE: A) for a "good" price amid the hype surrounding Life.
    Agilent provides bio-analytic and electronic measurement solutions to the communications, electronics, life sciences and chemical analysis industries, meaning it has a bit more of a diversified portfolio, serving not only the more »
  • Thermo Fisher – Life Technologies Deal Brings Benefits Along With A Huge Debt

    By Shas Dey - April 18, 2013 | Tickers: ILMN, LIFE, RHHBY, TMO

    On 15th April, Thermo Fisher Scientific (NYSE: TMO) announced that it would acquire Life Technologies (NASDAQ: LIFE) for $76 per share, 12% above its 12thApril share price of $68.

    The Deal

    After months of speculation of takeover, Life Technologies accepted Thermo Fisher’s bid over an offer from Sigma-Aldrich and a $65 per share bid from a consortium including Blackstone, Carlyle, KKR and Temasek Holdings. The price more »

  • This Huge Bidding War Is a Speculative Play

    By Anh HOANG - April 15, 2013 | Tickers: A, LIFE, TMO

    Since the beginning of the year, shareholders of Life Technologies (NASDAQ: LIFE) must be quite happy as its share price advanced significantly, from $49 per share to nearly $67 per share, a four-month gain of 36.7%. Recently, the company received a bid of $65 per share from a buyout group, which includes Blackstone Group, Carlyle Group, KKR & Co, and Temasek Holdings. However, Thermo Fisher Scientific (NYSE: TMO) placed a more »

  • These Companies Will Rise on M&A

    By Mohsin Saeed - April 13, 2013 | Tickers: DELL, LIFE, TMO

    The healthcare sector has given its investors pretty good returns in the last few quarters. Big pharmaceuticals have given solid capital appreciation on top of their solid dividend yields, but the surprise package has been the biotechnology industry. The industry has seen significant capital appreciation due to a large number of drugs getting FDA approval. The big pharmaceutical companies interested in promising candidates have also positively affected the stocks of more »

  • These Companies Will Rise on M&A

    By Mohsin Saeed - April 11, 2013 | Tickers: DELL, LIFE, TMO

    The healthcare sector has given its investors pretty good returns in the last few quarters. Big Pharmaceuticals have given solid capital appreciations on top of their solid dividend yields but the surprise package has been the biotechnology industry. The industry has seen significant capital appreciation due to a large number of drugs getting FDA approval. The big pharmaceutical companies interested in promising candidates have also positively affected the stock price more »

  • Investing in a Cheap Life

    By Marshall Hargrave - March 8, 2013 | Tickers: JNJ, LIFE, MRK, ONXX, SGEN

    Life Technologies (NASDAQ: LIFE) appears to have lost its buyout premium, but is the stock still worth investing in? The stock fell 7% earlier this week after reports that the buyout buzz for the company was cooling off. The maker of genetic testing equipment was previously reported to have engaged Deutsche and Moelis & Company to help shop around. Meanwhile, parties potentially interested in scooping up the company included Blackstone and more »

  • Three Reasons to Worry and One Theme That Can Outperform

    By Lee Samaha - February 22, 2013 | Tickers: ACT, COV, ILMN, LIFE, MYL

    Occasionally some of my friends ask me why I am hedged and market neutral in my investing. My answer is always the same. I invest for the long term, and the macro-environment remains very dangerous right now. I am confident in my ability to pick a portfolio that can outperform the market, but I can’t predict what is going to happen in the global economy, and the evidence is more »

  • Searching for the Next Franchise in Diagnostic Testing

    By Robert Hanley - January 25, 2013 | Tickers: GNMK, LIFE, DGX

    Ever since the human genome was completely sequenced in 2001, investment opportunities have abounded in the diagnostic testing industry, as exciting, new technologies have been built around this important scientific discovery.  The increasingly recurring nature of the testing business, and its strong profit margins, have brought private equity firms to the sector in search of buyouts.  The latest target is Life Technologies (NASDAQ: LIFE), which recently announced that it was more »

  • Top News on January 18 That You Might Have Missed!

    By Brian Nichols - January 19, 2013 | Tickers: INTC, LIFE, NES.DL, SNE, BA

    What happened today, why does it matter, and what could it mean for the future? Here's my take on Thursday’s company-specific and broader industry news that could have long-lasting effects on your portfolio.

    U.S. Secretary of Transportation changes his mind rather quickly

    Last week, the U.S. Secretary of Transportation Wood, said that Boeing's (NYSE: BA) 787 Dreamliner was safe and that he would fly more »

  • The Smart Money Has Been Eying the Future of DNA Sequencing: Should You?

    By Brendan O'Boyle - January 8, 2013 | Tickers: ILMN, LIFE, RHHBY

    Roche (NASDAQOTH: RHHBY) has a remarkable history of making attractive and well-timed acquisitions.  In 2009 they purchased Genentech and bought one of the most attractive companies on the market as blood ran through the streets. Recently Roche has turned its interest to a little known sequencing company named Illumina (NASDAQ: ILMN), but over this weekend they appear to have withdrawn the offer for a second time.

    In this context, it more »

  • Page 1 of 2